CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
MEDI4736drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02227667
NCT02227667Phase 2Completed
CompareCT.gov

Phase II Study to Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer

Memorial Sloan Kettering Cancer Center·interventional·Posted Aug 28, 2014·Updated Jun 18, 2021

In Brief

A Phase 2 clinical trial evaluating MEDI4736 for Advanced Colorectal Cancer. Completed, enrolled 16 participants across 1 site.

Detailed Summary

The purpose of this study is to find out what effects, good and/or bad, MEDI4736 has on the patient and cancer. MEDI4736 is a type of medication called an antibody. Antibodies are normal proteins in the body that help fight infections and possibly cancer. MEDI4736 is a special type of an antibody produced in a laboratory. MEDI4736 works by blocking a specific protein called the Programmed Death Ligand-1 (PDL-1), located on tumor cells.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Colorectal Cancer
CountriesUnited States
CollaboratorsMedImmune LLC, AstraZeneca

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 28, 2014
Enrollment StartDec 2, 2014
Primary CompletionJun 29, 2020
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 11.8 years ago

Interventions

MEDI4736drug

Patients will be seen the day of administration of MEDI4736. A medical history, with particular reference to toxicities, including medication review, and physical examination will be conducted at each treatment visit.